Aaron Moss

📑 Sifting through lengthy research papers and articles can slow down discovery. Open Targets now uses LLM-powered summaries to tackle this challenge—helping researchers quickly uncover key insights about drug targets and therapeutic opportunities. Discover how this feature accelerates your research! ⚡https://lnkd.in/eY7pSfAH #OpenTargets #DrugDiscovery #BiomedicalResearch #LLMs #LifeSciences #AIPowered #ScientificInnovation

10

#Bioanalytical #drugdevelopment can be challenging. Come join us for a day of learning and sharing your concerns (or experiences) at PBSS International workshop "Current State of Bioanalysis for Biologics and Cell/Gene Therapy Products" Refining Established Approaches for New Complex Therapies" #cellandgenetherapies #biologics

18

FDA Guidance on CGT Products: A New Era for Regulatory Clarity? The FDA’s draft guidance on CGT products is a critical resource for sponsors. It offers clear expectations for IND submissions, expedited pathways, and product characterization. Our team sees this as an opportunity for sponsors to take a more proactive approach with regulators - especially through early meetings like INTERACT and pre-IND. But we know the execution isn’t always straightforward. What are your thoughts on the guidance? Are you seeing clearer pathways, or do the hurdles remain? 👉 Access the guidance here: https://lnkd.in/eQbNpvJK #FDA #CGT #CellTherapy #GeneTherapy #INTERACT #preIND

4

Lake N. Paul, PhD. is in San Diego at the Biotechnology Innovation Organization #BIO2024 conference meeting with colleagues & future clients. Connect with him in person to learn about how, as a Collaborative Research Organization, we are best positioned to support your analytical program. #aav #genetherapy #rarediseases #biophysics #STEM #STEMPhilly #biochemistry #celltherapy #bioanalysisllc #PhillyBusiness #phillyscience

9

🌟 Best of #ASMS2024 🌟 Fintiede Solutions is thrilled to share the groundbreaking advancements unveiled by Evosep at the #ASMS2024 conference in Anaheim! Evosep continues to push the boundaries in the field of proteomics, introducing innovations that are set to transform research and clinical diagnostics. 🔬 Key Innovations Announced: Fully Automated Workflows: - Capable of processing over 500 plasma samples per day. - Maximizes efficiency and minimizes manual intervention. - Ideal for accelerating drug discovery and supporting large-scale translational research. - Reduces cost per sample and environmental impact. Whisper™ Zoom Methods: - Enhances scalability and sensitivity for detailed and accurate proteomic analyses. - Unlocks the ability to detect low-abundant proteins and identify novel biomarkers. - Facilitates deeper biological insights into disease pathways. Evosep Biolabs: Center of Excellence for High Throughput Proteomics: - Specializes in high-throughput proteomics with automated sample preparation. - Offers access to state-of-the-art LC-MS/MS workflows and expert assay development. - Provides scalable capacity for outsourcing proteomics research projects. 🏆 Impact and Vision: Evosep's innovations are designed to make clinical proteomics 100x more robust and 10x faster, revolutionizing the landscape of proteomics research. These advancements are particularly aimed at accelerating drug discovery and enhancing proteomics-based diagnostics, ultimately improving patient care. We are proud to be part of this journey and look forward to the incredible breakthroughs these technologies will enable in the near future. #Evosep #Proteomics #ASMS2024 #ScientificInnovation #DrugDiscovery #TranslationalResearch #Biomarkers #ClinicalDiagnostics #automation #whisper

2

SDBN Feed: Candid Therapeutics unwraps three new collaborations to discover and develop T-cell engager antibodies https://lnkd.in/g4rKJTSk Candid Therapeutics, a new San Diego biotech bent on becoming a leader in the emerging T-cell engager space, has unwrapped three new research collaborations focusing on autoimmune diseases. Candid will partner with EpimAb Biotherapeutics, Nona [...]

1

🚀 Exciting News for Biocom California Members! 🚀 Your fellow member, Transition Services, Inc. (TSI), is hosting a game-changing, hour-long webinar on July 16th, 2024, at 11:00 AM PST that you will not want to miss! Discover a little-known separation benefits structure that can drastically cut your company's costs while providing an innovative alternative to traditional severance. 💡 𝐖𝐡𝐲 𝐀𝐭𝐭𝐞𝐧𝐝? 𝟏. 𝐈𝐧-𝐝𝐞𝐩𝐭𝐡 𝐔𝐧𝐝𝐞𝐫𝐬𝐭𝐚𝐧𝐝𝐢𝐧𝐠: Learn about SUB Plans, an IRS-sanctioned and tax-advantaged alternative to severance. 𝟐. 𝐋𝐞𝐠𝐚𝐥 𝐚𝐧𝐝 𝐓𝐚𝐱 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬: Understand the benefits associated with SUB Plans. 𝟑. 𝐈𝐦𝐩𝐥𝐞𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬: Discover how to implement this flexible and cost-effective severance alternative. 𝟒. 𝐍𝐞𝐭𝐰𝐨𝐫𝐤𝐢𝐧𝐠 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬: Expand your professional network. Click the link below for more details and to secure your spot for this must-attend virtual event. Do not miss out on the opportunity to revolutionize your approach to employee separations! #employeeseparations #severancealternative #hrbenefits #supplementalunemploymentbenefits #costsavings #strategicplanning

2

As we approach the 15th Annual @World ADC meeting in San Diego, we are excited to explore potential partnerships and collaborations in the cutting-edge field of Antibody Drug Conjugates (ADCs) for oncology. ADCs are transforming cancer treatment by precisely targeting cancer cells, administering potent therapies directly where they are needed, while protecting healthy tissue in the process. We are particularly looking forward to Scientific Officer Lynn Kamen’s presentation titled, "Bioanalytical Strategies for Antibody Drug Conjugate Development," scheduled for November 5th from 6:30-7:30 PM. In her talk, Dr. Kamen will delve into vital bioanalytical strategies for assessing ADC pharmacokinetics and immunogenicity, emphasizing the significance of both molecular components for ensuring efficacy and safety. Join us in connecting with researchers and industry leaders as we work towards advancing oncology treatments. We can't wait to see you at booth 518 in San Diego! https://bit.ly/4dTJZVa #WorldADC #ADC #PharmaInnovation #Biotech #DrugDevelopment #BioAgilytix #AntibodyDrugConjugates #InnovationInBiotech

42

CRS3123 is a small molecule protein synthesis inhibitor that acts on the novel target methionyl-tRNA synthetase (MetRS). CRS3123 has numerous potential advantages over current CDI therapies. Learn more about C. difficile Infection (CDI) and the Phase 2 study of CRS3123 here: https://bit.ly/3zhg5Kb

11

CRS3123 is a small molecule protein synthesis inhibitor that acts on the novel target methionyl-tRNA synthetase (MetRS). CRS3123 has numerous potential advantages over current CDI therapies. Learn more about C. difficile Infection (CDI) and the Phase 2 study of CRS3123 here: https://bit.ly/3zhg5Kb

3